Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clal Biotechnology IndustriesXTAE:CBI -0.42%18 PB Ratio is 1.85 as of Aug. 14, 2026, which is 150% above its 10-year median of 0.74. GuruFocus rates XTAE:CBI with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 1,220 Biotechnology companies, Clal Biotechnology Industries ranks better than 65.41% on this metric.
Clal Biotechnology Industries Ltd stock PB Ratio (=1.9) is close to 10-year high of 1.9.
The historical rank and industry rank for Clal Biotechnology Industries's PB Ratio or its related term are showing as below:
XTAE:CBI'
s PB Ratio Range Over the Past 10 Years
Min: 0.39 Med: 0.74 Max: 1.9
Current: 1.85
During the past 13 years, Clal Biotechnology Industries's highest PB Ratio was 1.90. The lowest was 0.39. And the median was 0.74.
XTAE:CBI's PB Ratio is ranked better than 65.41% of 1220
companies
in the Biotechnology industry
Industry Median: 2.905
vs XTAE:CBI: 1.85
During the past 12 months, Clal Biotechnology Industries's average Book Value Per Share Growth Rate was -44.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -45.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -40.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -26.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Clal Biotechnology Industries was 65.40% per year. The lowest was -45.70% per year. And the median was -19.60% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Clal Biotechnology Industries PB Ratio Related Terms
Clal Biotechnology Industries PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Clal Biotechnology Industries's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clal Biotechnology Industries PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clal Biotechnology Industries's PB Ratio distribution charts can be found below:
* The bar in red indicates where Clal Biotechnology Industries's PB Ratio falls into.
Clal Biotechnology Industries PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Clal Biotechnology Industries (XTAE:CBI) has a PB Ratio of 1.85 as of Aug. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Clal Biotechnology Industries and its competitors. This is 150% above median its historical median of 0.74. Over the past decade, Clal Biotechnology Industries' PB Ratio has ranged from 0.39 to 1.90. According to the industry distribution chart, Clal Biotechnology Industries ranks #422 out of 1220 companies in the Biotechnology industry, placing it in the top 34.6%.
Is Clal Biotechnology Industries' PB Ratio too high?
Clal Biotechnology Industries' current PB Ratio of 1.85 is 150% above median its 10-year median of 0.74. Over the past 10 years, this metric has ranged from a low of 0.39 to a high of 1.90. The Biotechnology industry median PB Ratio is 2.91. Clal Biotechnology Industries' value of 1.85 is 36.3% below this industry median. Based on the distribution chart, Clal Biotechnology Industries ranks #422 out of 1220 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Clal Biotechnology Industries has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Clal Biotechnology Industries' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clal Biotechnology Industries ranks #422 out of 1220 companies for PB Ratio. This puts Clal Biotechnology Industries in the upper half of its industry. The industry median PB Ratio is 2.91. Clal Biotechnology Industries' value of 1.85 is 36.3% below this benchmark. Historically, Clal Biotechnology Industries' own PB Ratio has ranged from 0.39 to 1.90 over the past decade. While the company's 10-year median is 0.74 vs. the industry median of 2.91, Clal Biotechnology Industries has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.91, based on 1,220 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clal Biotechnology Industries's current PB Ratio of 1.85 is 36.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Clal Biotechnology Industries and its competitors. For the Biotechnology industry, the median PB Ratio is 2.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clal Biotechnology Industries's current PB Ratio is 1.85, which is 150% above median its own 10-year median of 0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clal Biotechnology Industries stock overvalued right now?
Clal Biotechnology Industries (XTAE:CBI) has a current PB Ratio of 1.85. The current PB Ratio is 1.85, which is 150% above median its 10-year median of 0.74 and 36.3% below the Biotechnology industry median of 2.91. Clal Biotechnology Industries' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Clal Biotechnology Industries (XTAE:CBI), the current PB Ratio is 1.85 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Clal Biotechnology Industries Ltd is a life sciences investment company. The company invests in companies ranging from seed to maturity, both public and private. Its portfolio of investments includes from heavy industry to biotechnology, hi-tech and energy companies.
18GF Score
Get the complete analysis for XTAE:CBI
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:CBI has been successfully added to your 
